Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved

Abstract: Because the chronobiotic and cytoprotective molecule melatonin diminishes with age, its involvement in postmenopausal and senescence pathology has been considered since long. One relevant melatonin target site in aging individuals is bone where melatonin chronobiotic effects mediated b...

Descripción completa

Detalles Bibliográficos
Autor principal: Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: John Wiley & Sons 2024
Materias:
ALOMETRIA
FISIOLOGIA OSEA
CRONOBIOTICA
RITMOS CIRCADIANOS
CITOPROTECTOR
MELATONINA
OSTEOPOROSIS
ESTRES OXIDATIVO
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/18301
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-18301
record_format dspace
spelling I33-R139-123456789-183012024-06-19T05:01:43Z Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved Cardinali, Daniel Pedro ALOMETRIA FISIOLOGIA OSEA CRONOBIOTICA RITMOS CIRCADIANOS CITOPROTECTOR MELATONINA OSTEOPOROSIS ESTRES OXIDATIVO Abstract: Because the chronobiotic and cytoprotective molecule melatonin diminishes with age, its involvement in postmenopausal and senescence pathology has been considered since long. One relevant melatonin target site in aging individuals is bone where melatonin chronobiotic effects mediated by MT1 and MT2 receptors are demonstrable. Precursors of bone cells located in bone marrow are exposed to high quantities of melatonin and the possibility arises that melatonin acts a cytoprotective compound via an autacoid effect. Proteins that are incorporated into the bone matrix, like procollagen type I c‐peptide, augment after melatonin exposure. Melatonin augments osteoprotegerin, an osteoblastic protein that inhibits the differentiation of osteoclasts. Osteoclasts are target cells for melatonin as they degrade bone partly by generating free radicals. Osteoclast activity and bone resorption are impaired via the free radical scavenger properties of melatonin. The administration of melatonin in chronobiotic doses (less than 10 mg daily) is commonly used in clinical studies on melatonin effect on bone. However, human equivalent doses allometrically derived from animal studies are in the 1–1.5 mg/kg/day range for a 75 kg human adult, a dose rarely used clinically. In view of the absence of toxicity of melatonin in phase 1 pharmacological studies with doses up to 100 mg in normal volunteers, further investigation is needed to determine whether high melatonin doses have higher therapeutic efficacy in preventing bone loss. 2024-06-18T11:12:32Z 2024-06-18T11:12:32Z 2023 Artículo Cardinali, D. P. Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved [en línea]. Journal of Pineal Research. 2023, 76 (1). doi:10.1111/jpi.12931. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/18301 0742-3098 (impreso) 1600-079X (online) https://repositorio.uca.edu.ar/handle/123456789/18301 10.1111/jpi.12931 38083808 eng Acceso restringido http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf John Wiley & Sons Journal of Pineal Research. 2023, 76 (1).
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic ALOMETRIA
FISIOLOGIA OSEA
CRONOBIOTICA
RITMOS CIRCADIANOS
CITOPROTECTOR
MELATONINA
OSTEOPOROSIS
ESTRES OXIDATIVO
spellingShingle ALOMETRIA
FISIOLOGIA OSEA
CRONOBIOTICA
RITMOS CIRCADIANOS
CITOPROTECTOR
MELATONINA
OSTEOPOROSIS
ESTRES OXIDATIVO
Cardinali, Daniel Pedro
Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved
topic_facet ALOMETRIA
FISIOLOGIA OSEA
CRONOBIOTICA
RITMOS CIRCADIANOS
CITOPROTECTOR
MELATONINA
OSTEOPOROSIS
ESTRES OXIDATIVO
description Abstract: Because the chronobiotic and cytoprotective molecule melatonin diminishes with age, its involvement in postmenopausal and senescence pathology has been considered since long. One relevant melatonin target site in aging individuals is bone where melatonin chronobiotic effects mediated by MT1 and MT2 receptors are demonstrable. Precursors of bone cells located in bone marrow are exposed to high quantities of melatonin and the possibility arises that melatonin acts a cytoprotective compound via an autacoid effect. Proteins that are incorporated into the bone matrix, like procollagen type I c‐peptide, augment after melatonin exposure. Melatonin augments osteoprotegerin, an osteoblastic protein that inhibits the differentiation of osteoclasts. Osteoclasts are target cells for melatonin as they degrade bone partly by generating free radicals. Osteoclast activity and bone resorption are impaired via the free radical scavenger properties of melatonin. The administration of melatonin in chronobiotic doses (less than 10 mg daily) is commonly used in clinical studies on melatonin effect on bone. However, human equivalent doses allometrically derived from animal studies are in the 1–1.5 mg/kg/day range for a 75 kg human adult, a dose rarely used clinically. In view of the absence of toxicity of melatonin in phase 1 pharmacological studies with doses up to 100 mg in normal volunteers, further investigation is needed to determine whether high melatonin doses have higher therapeutic efficacy in preventing bone loss.
format Artículo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
author_sort Cardinali, Daniel Pedro
title Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved
title_short Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved
title_full Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved
title_fullStr Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved
title_full_unstemmed Melatonin as a chronobiotic/cytoprotective agent in bone: doses involved
title_sort melatonin as a chronobiotic/cytoprotective agent in bone: doses involved
publisher John Wiley & Sons
publishDate 2024
url https://repositorio.uca.edu.ar/handle/123456789/18301
work_keys_str_mv AT cardinalidanielpedro melatoninasachronobioticcytoprotectiveagentinbonedosesinvolved
_version_ 1807949561970294784

Ejemplares similares